In a single-arm, open-label, eight week, pilot study, we reported that pentoxifylline (PTX) reduced circulating levels of interferon-γ-induced protein 10 (IP-10) and soluble vascular cell adhesion molecule-1 (sVCAM-1) and improved endothelial function (measured as flowmediated dilation (FMD) of the brachial artery) in HIV-infected patients not receiving ART [4] . However, in a randomized, placebo-controlled trial of PTX in a similarly untreated population, we did not confirm that PTX reduced inflammation or improved endothelial function [5] . In fact, PTX unexpectedly led to significantly increased circulating soluble tumor necrosis factor-1 (sTNFR1) levels compared to placebo in this trial. However, the potential effects of PTX on FMD and inflammation in a population initiating ART are unknown. Thus, we conducted a randomized, placebo-controlled, single-center pilot trial of PTX 400mg thrice daily given for 48 weeks in patients concurrently initiating ART (ClinicalTrials.gov NCT00864916).
The eligibility criteria, procedures, and methods in the current study were similar to our previous trial in patients not receiving ART [5] . Participants were instructed to start ART, as chosen by the primary HIV provider, and the study drug together at study entry. Study visits occurred at Weeks 0, 8, 24, and 48. No restrictions were made on the ART components or initial CD4 cell count. The primary endpoint was change in brachial artery FMD was measured using B-mode ultrasound after 5 minutes of forearm cuff occlusion to a suprasystolic pressure, as previously described [5] . All scans were performed by a certified sonographer and read at the University of Wisconsin, the brachial artery reactivity testing reading center for the NHLBI HIV-CVD collaborative, by a single reader [5] . This trial was approved by the Indiana University Institutional Review Board; all participants provided written, informed consent. The use of pentoxifylline for the purpose of reducing inflammation and improving endothelial function is unlabeled and considered investigational.
Linear mixed-effects models were constructed to evaluate changes in FMD and the circulating biomarkers both between groups and over time. Additional models were constructed to evaluate the effects of individual biomarkers (listed in Table 1 ), baseline brachial artery diameter, CD4 cell count, and HIV-1 RNA levels on changes in FMD. We also constructed linear mixed effects models assessing treatment group by week interactions and including HIV-1 RNA levels at each study visit as a covariate. Two-sided P-values <0.05 were considered statistically significant.
We enrolled 19 participants (10 in the PTX group, 9 in the placebo group). At weeks 8, 24, and 48, the numbers of participants remaining in the PTX and placebo arms were, respectively, 9 and 7, 8 and 6, and 4 and 5. The baseline characteristics of the enrolled participants are shown in Table 1 . The two study groups were balanced. The majority of the study participants were black men with over half being current smokers. Table 1 shows the baseline brachial artery diameter, FMD, and nitroglycerin-mediated dilation (NTGMD) values at each time point. The changes in FMD (SD) in the PTX vs. the placebo groups at weeks 8, 24, and 48 were, respectively, −3.60% (2.54) vs. 1.91% (2.46), 0.72% (3.71) vs. 1.07% (1.77), and 0.01 (3.22) vs. 2.23 (1.42). In all models constructed comparing these changes in FMD, even after adjustment for changes in HIV-1 RNA levels, we did not find significant differences between the PTX and placebo groups at any time point. There were also no significant changes between groups or over time in all models for nitroglycerinmediated dilation (NTGMD).
In our models assessing the changes in the circulating biomarkers, we found smaller declines from baseline in the PTX group vs. the placebo group in levels of monocyte chemoattractant protein-1 (MCP-1, pg/mL) [ 
changes between groups in the other biomarkers assessed at any time point.
There was one serious adverse event in the PTX group (suicidal ideation with overdose of a non-study drug which did not result in death) but none in the placebo group. There was a non-significantly higher number of gastrointestinal adverse events (nausea, flatus, diarrhea) with PTX (6 of 10 participants) compared to placebo (2 of 9 participants), none of which were treatment-limiting.
In this pilot, randomized, placebo-controlled trial, we did not find that PTX improved endothelial function in HIV-infected patients over the first year of ART. These results are in line with our previous trial in patients not receiving ART. However, in the current trial, we found that PTX may attenuate reductions in MCP-1 and IL-6 and possibly greater reductions in ADMA compared to placebo. We did not find any significant effects of PTX on sTNFR1 as we had in our previous trial of PTX in patients not receiving ART. To our knowledge, these potential effects of PTX on the proatherogenic molecules MCP-1, IL-6, and ADMA have not previously been described. Although we cannot fully explain these latter results, these data add to our previous trial in those not receiving ART that PTX may have mixed and potentially adverse effects on inflammatory and endothelial activation pathways. Our results are limited by the small sample size, so they must be considered exploratory as we cannot exclude the possibility a larger, longer study or one that involved patients chronically treated with ART may have found an effect of PTX on vascular function. We acknowledge that the numbers of statistical tests performed may have led to false positive findings, especially in regards to the biomarker comparisons.
Because PTX is considered safe and very well-tolerated [5] [6] [7] , it has been considered an ideal anti-inflammatory agent for chronic inflammatory conditions. For this reason, it is currently being studied in trials in HIV-uninfected patients for non-alcoholic steatohepatitis, irritable bowel syndrome, chronic kidney disease, and congestive heart failure (ClinicalTrials.gov). However, the lack of improvement in endothelial function and the potentially worrisome effects on several proatherogenic inflammatory molecules in our trials should be considered before using PTX in future trials in HIV-infected patients.
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Page 5 Table 1 Baseline (Week 0) characteristics of the study groups and vascular measures during the trial. Data presented as means (SD) or as n (%). Student's t-tests and associated P-values were used for comparison between the pentoxifylline (PTX) and placebo groups. GFR estimated using the 2012 CKD-EPI creatinine-cystatin C combined equation. At weeks 8, 24, and 48, the numbers of participants remaining in the PTX and placebo arms were, respectively, 9 and 7, 8 and 6, and 4 and 5. MCP-1, monocyte chemoattractant protein-1; hsCRP, high sensitivity C-reactive protein; ADMA, asymmetric dimethyl arginine; IL-6, interleukin-6; sVCAM-1, soluble vascular cell adhesion molecule-1; sTNFR1, soluble tumor necrosis factor receptor 1; IP-10, interferon-gamma-inducible protein-10; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance
